ALK	anaplastic lymphoma kinase
ARA	acid-reducing agent
AUC	area under the concentration–time curve
BCL-2	B-cell lymphoma 2
BCRP	breast cancer resistance protein (ABCG2)
BCS	Biopharmaceutics Classification System
BID	twice daily
BTK	Bruton tyrosine kinase
CDK	cyclin-dependent kinase
CLL	chronic lymphocytic leukemia
Cmax	maximum plasma concentration
CYP	cytochrome P450
DDI	drug–drug interaction
EGFR	epidermal growth factor receptor
EMA	European Medicines Agency
F	oral bioavailability
FDA	Food and Drug Administration
GI	gastrointestinal
H2RA	histamine H2-receptor antagonist
HER2	human epidermal growth factor receptor 2
HLA	human leukocyte antigen
MATE	multidrug and toxin extrusion
OATP	organic anion transporting polypeptide
OCT	organic cation transporter
PARP	poly(ADP-ribose) polymerase
P-gp	P-glycoprotein (ABCB1)
PK	pharmacokinetics
PPI	proton pump inhibitor
SmPC	summary of product characteristics
TDM	therapeutic drug monitoring
TKI	tyrosine kinase inhibitor
TLS	tumor lysis syndrome
UGT	uridine diphosphate glucuronosyltransferase
VEGFR	vascular endothelial growth factor receptor